Phase 4 Crohn's Disease and Colitis Trial, Not Yet Recruiting NCT07417696 Sponsor: Chinese Medical Association Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 4 Crohn's Disease and Colitis Trial, Not Yet Recruiting

NCT07417696
Not Yet Recruiting Phase 4

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults between 18 and 75 years of age.
  • People who have a confirmed diagnosis of Crohn's disease, shown through imaging, tissue samples, or a camera examination of the gut.
  • People with active Crohn's disease at the time of screening, measured using a standard scoring system called the CDAI, with a score between 220 and 450.
  • People whose heart, kidney, and liver function are considered adequate by the study doctor, based on blood tests, a physical check-up, and medical history, with no findings that would put them at undue risk.
  • People who are willing and able to sign a written consent form agreeing to take part in the trial.
  • People who agree to attend all required study visits, including up to 3 camera examinations of the gut.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have used certain biologic medicines (such as infliximab, adalimumab, ustekinumab, or vedolizumab) within the 8 weeks before screening.
  • People who have taken supplements containing fish oil or similar lipid supplements (such as macadamia oil, krill oil, flaxseed, primrose oil, or sea buckthorn oil) within the 8 weeks before screening.
  • People who have had surgery on the intestine or any other Crohn's disease-related operation at any point in the past.
  • People with a history of, or currently living with, a long-term or repeatedly occurring infectious disease.
  • People who have a current or past history of cancer.
  • People who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  • People with a known allergy or sensitivity to infliximab or palmitoleic acid preparations.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Chinese Medical Association
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
31 March 2029

Primary endpoints

Complete mucosal healing

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov